Compare Sanofi SA (SNY) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Verisign, Inc. — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Verisign, Inc. trades at $303.74 (market cap $26.92B). The key difference: Sanofi SA is far larger — about 3.5× Verisign, Inc.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Verisign, Inc. for 123 Days on average.
| SNY | VRSN | |
|---|---|---|
Market Cap | $95.18B | $26.92B |
Volume | 2,995,646 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $52.34 | $310.00 |
52-Week Low | $39.51 | $211.49 |
Typical Hold Time | 94 Days | 123 Days |
Enterprise Value | $114.48B | $28.23B |
Dividend Yield | 6.01% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
VeriSign (VRSN) trades at $297.79, up 1.21% today, with a bullish technical signal and strong fundamentals including a 49.77% net income margin. Recent earnings show mixed quarterly beats, while institutional buying and a pending Q3 2026 report highlight investor interest. The stock faces resistance near $299, with support at $296.
Outlook remains positive with a consensus price target of $348, driven by robust cash flow and domain growth, though risks include an antitrust lawsuit and high valuation multiples. The buy-rated stock offers upside potential but requires monitoring of legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
